Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of January 2019, with the report dated January 22, 2019. The filing primarily discloses a definitive agreement entered into on January 18, 2019, for a registered direct offering of American Depositary Shares (ADSs) to a single institutional investor.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2,350,000 from the sale of 2,238,096 ADSs.
- Offering Price: $1.05 per ADS.
- Warrants Issued: Unregistered warrants to purchase 2,238,096 ADSs (1:1 ratio) at an exercise price of $1.30 per ADS, expiring five and a half years from issuance.
- Placement Agent Fees: 6% of the aggregate purchase price, plus a $50,000 non-accountable expense allowance and $10,000 in clearing expenses.
- Placement Agent Warrants: Warrants equal to 5% of the ADSs sold (111,905 warrants) at $1.30 per ADS.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures for the period.
Material Changes and Covenants
The transaction represents a material capital raise event. Key covenants include:
- Lock-up Period: The Company agreed not to issue or announce the issuance of any ADSs, ordinary shares, or equivalents for 90 days following the closing, subject to customary exceptions.
- Variable Rate Transaction Restriction: A 13-month prohibition on entering into "variable rate transactions" following the closing.
- Registration Obligation: The Company must file a registration statement for the resale of warrant shares by February 17, 2019, and use best efforts to have it declared effective within 60 days of closing.
Outlook, Risks, and Contingencies
The offering is expected to close on or about January 23, 2019, subject to customary closing conditions. The filing includes a standard warning concerning forward-looking statements, noting that the closing is not guaranteed and depends on the satisfaction of conditions and contingencies. If these conditions are not met, the offering may not close. The Company undertakes no obligation to update these statements unless required by law.
Investor Verification Checklist
- Confirm the actual closing date of the offering and whether all customary conditions were satisfied.
- Verify the net proceeds received after deducting the 6% placement fee, expense allowance, and clearing costs.
- Monitor the filing and effectiveness of the registration statement for the warrant shares by the February 17, 2019 deadline.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant (Exhibit 10.2) for specific adjustment provisions and cashless exercise terms.
- Check subsequent filings for any breach of the 90-day lock-up or 13-month variable rate transaction restrictions.